Collaborative Neuroscience Network LLC

1. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,795,448 8 payments
2. Biogen, Inc. $573,519 8 payments
3. Boehringer Ingelheim Pharmaceuticals, Inc. $520,688 11 payments
4. Supernus Pharmaceuticals, Inc. $282,966 38 payments
5. Neurocrine Biosciences, Inc. $181,586 25 payments
6. ACADIA Pharmaceuticals Inc $156,595 70 payments
7. Horizon Therapeutics plc $72,747 1 payment
8. Boehringer Ingelheim International GmbH $46,065 37 payments
9. Biohaven Pharmaceuticals, Inc. $41,423 10 payments
10. Acorda Therapeutics, Inc $36,501 6 payments

1. A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder $1,648,435 2 payments
2. A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) $485,001 3 payments
3. Adjunctive Computerized Cognitive Training CCT $390,705 7 payments
4. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of Spn-812 in Adults With Attention-Deficit/Hyperactivity Disorder (Adhd) $160,292 13 payments
5. The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine $158,849 19 payments
6. PoC in Prevention of Relapse $143,800 4 payments
7. An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Spn-812 in Adults With Attention- Deficit/Hyperactivity Disorder $122,674 25 payments
8. A Phase Iiib Multi-Center, Open-Label, Mirror-Image, Study in Adult Subjects With Schizophrenia Treated Prospectively for 6-Months With Abilify Mycite $76,506 2 payments
9. A Phase 2A Single-Arm, Prospective, Open-Label Pilot Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With Vib4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving A Kidney Transplant $72,747 1 payment
10. A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Arm Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Drobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Negative Symptoms of Schizophrenia $54,047 1 payment

1. Patient care $16,020 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.